A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma
Crossref DOI link: https://doi.org/10.1186/s13569-015-0029-8
Published Online: 2015-05-16
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Seddon, Beatrice
Scurr, Michelle
Jones, Robin L
Wood, Zoe
Propert-Lewis, Cerys
Fisher, Cyril
Flanagan, Adrienne
Sunkersing, Jonanthan
A’Hern, Roger
Whelan, Jeremy
Judson, Ian